Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Jiangsu Recbio Technology Co Ltd

2179:HKG.HZ

Jiangsu Recbio Technology Co Ltd

Actions
  • Price (HKD)8.85
  • Today's Change0.31 / 3.63%
  • Shares traded8.00k
  • 1 Year change-19.40%
  • Beta--
Data delayed at least 15 minutes, as of Oct 15 2024 08:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-599.19m
  • Incorporated2012
  • Employees507.00
  • Location
    Jiangsu Recbio Technology Co LtdNo. 888 Yaocheng AvenueChina Medical CityTAIZHOU ChinaCHN
  • Phone+86 52 386818860
  • Websitehttps://www.recbio.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.